Drug intelligence / Profile preview

encelimab

Development stage: Phase 1
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

Encelimab is a humanized IgG4 monoclonal antibody developed by AnaptysBio and GSK. It functions as an immune checkpoint inhibitor by targeting Lymphocyte-activation gene 3 (LAG-3), blocking its interaction with MHC II and thereby enhancing T-cell activation. It has been investigated for the treatment of advanced/metastatic solid tumors, both as a monotherapy and in combination with other immunotherapies like dostarlimab.

Other names: encelimab

Targets

LAG3 (Lymphocyte activation Gene-3 protein)

Beyond the preview

Go deeper on encelimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on encelimab.

Explore the full profile